No apparent transmission of transgenic α–synuclein into nigrostriatal dopaminergic neurons in multiple mouse models
© Sastry et al. 2015
Received: 7 October 2015
Accepted: 1 December 2015
Published: 3 December 2015
α–synuclein (α–syn) is the main component of intracytoplasmic inclusions deposited in the brains of patients with Parkinson’s disease (PD) and certain other neurodegenerative disorders. Recent studies have explored the ability of α–syn to propagate between or across neighboring neurons and supposedly “infect” them with a prion–like mechanism. However, much of this research has used stereotaxic injections of heterologous α–syn fibrils to induce the spreading of inclusions in the rodent brains. Whether α–syn is able to transmit from the host cells to their neighboring cells in vivo is unclear.
Using immunestaining, we examined the potential propagation of α–syn into nigrostriatal dopaminergic (DA) neurons in three lines of transgenic mice that overexpress human wild–type α–syn (hα–syn) in different neuron populations.
After testing for three different routes by which hα–syn propagation might occur, we were unable to find any evidence that hα–syn behaved like a prion and could be transmitted overtime into the DA neurons initially lack of hα–syn expression.
In transgenic mice hα–syn does not have the ability to propagate at pathologically significant levels between or across neurons. It must be noted that these observations do not disprove the studies that show its prion–like qualities, but rather that propagation is not detectable in transgenic models that do not use any injections of heterologous proteins or viral vectors to induce a spreading state.
KeywordsParkinson’s disease α-synuclein Propagation Dopaminergic neurons Transgenic mice
Parkinson’s disease (PD) is the second most common neurodegenerative disease, causing debilitating motor and non–motor symptoms [1, 2]. PD is pathologically characterized by the death of nigrostriatal dopaminergic neurons in the ventral substantia nigra pars compacta (SNc) of the midbrain, as well as the presence of intracytoplasmic inclusions known as Lewy bodies (LBs) and Lewy neurites (LNs). The main component of these inclusions is α–synuclein (α–syn) . α–syn is a small 140 amino acid protein that is thought to play a role in synaptic vesicle release . Both missense and multiplication mutations of α–syn are linked to early onset familial forms of PD . How mutant α–syn leads to SNc DA neuron loss and LB/LN formation has been under intense investigation ever since.
PD patient brains seem to show a stereotypical appearance of LB/LN pathology that can be mapped into various stages of disease evolution: lesions first appear in the glossopharyngeal and vagal nerves, continue to the SNc DA neurons, and eventually cover the primary sensory and motor cortices . Subsequent studies have hypothesized that α–syn intercellular propagation may be responsible for this stereotypical pathology and have provided evidence both in vitro and in vivo [7–10]. The in vivo studies have primarily focused on using intracerebral inoculations of diseased brain homogenate or preformed α–syn fibrils to study development and progression of PD pathology [9, 10]. In wild–type control mice, injections of preformed fibrils of α–syn are sufficient to initiate LB/LN pathology in regions anatomically connected to the site of injection . Such intracerebral injections can also accelerate the formation of LBs and LNs in otherwise asymptotic mice  and can be seen over serial passages of inoculations . This has been further confirmed by a study where inoculation with homogenate from either A53T human α–syn transgenic mouse brains or multiple system atrophy patient brains resulted in disease pathology in mice that do not otherwise develop any spontaneous illness . Moreover, this phenomenon has been studied in primates, and propagation is evident in macaque monkeys in addition to rodents . Increasing evidence thus suggests that α–syn potentially behaves in a prion–like manner, where mutated α–syn can be transmitted from cell to cell and spread the pathology .
While these studies provide very compelling results to show the prion–like qualities of α–syn, much of the methodology involves artificial injections and inoculations. This triggered us to determine if α–syn propagation could be observed in mice that overexpress human wild–type α–syn (hα–syn), without the need for any injections. Therefore, we generated multiple lines of transgenic mice that overexpress hα–syn in different neuron populations inside and outside of the SNc. We then examined three different routes by which α–syn may propagate into the SNc DA neurons, including long–range propagation from anatomically separated regions, short–distance transmission from presynaptic spiny projection neurons (SPNs), and neighboring DA neurons. Unlike previous inoculation experiments, we found no evidence that α–syn could propagate and possess prion–like qualities in any of our three modes of study, thus questioning α–syn propagation as the method of disease progression in PD.
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institutional Animal Care and Use Committees of the National Institute of Child Health and Human Development, NIH (Permit Number: 13–040). All surgery was performed under ketamine anesthesia, and all efforts were made to minimize suffering.
To generate tetO–SNCA transgenic mice, human wild–type α-syn (SNCA) cDNA coding region was inserted into the mouse prion protein (pPrP)–tetO gene expression vector (a gift from Dr. David Borchelt, University of Florida, Gainesville, FL), which is controlled by the tetracycline-responsive promoter (tetP) . The tetO-SNCA expression construct was then purified and microinjected into fertilized oocytes derived from C57BL/6 J mice. The founder mice were crossed with wild-type C57BL/6 J mice to produce the F1 generation. Pitx3–tTA knock–in mice were created as described previously . Drd1a–rtTA mice were obtained from Jackson Laboratories (Bar Harbor, ME). All mice were housed in a 12 h light/dark cycle and fed regular diet ad libitum. All mouse work follows the guidelines approved by the Institutional Animal Care and Use Committees of the National Institute of Child Health and Human Development, NIH.
Genomic DNA was prepared from tail biopsy using DirectPCR Lysis Reagent (Viagen Biotech, Inc., Los Angeles, CA) and subjected to PCR amplification using specific sets of PCR primers for each genotype, including Pitx3–tTA transgenic mice (Pitx3–F: GACTGGCTTGCCCTCGTCCCA and Pitx3–R: GTGCACCGAGGCCCCAGATCA), tetO–SNCA transgenic mice (PrpEx2–F: TACTGCTCCATTTTGCGTGA and SNCA–R: TCCAGAATTCCTTCCTGTGG), Drd1a–rtTA transgenic mice (14915–F: ACCGGAAGTGCTTTCCTTCT and 14916–R: CGACTTGATGCTCTTGATCTTCC).
Immunohistochemistry and light microscopy
Mice were sacrificed and then perfused via cardiac infusion with 4 % paraformaldehyde in cold PBS, followed by post–fixation in the same solution overnight. To obtain sections, brain tissues were removed and submerged in 30 % sucrose for 24 h and sectioned at 30 μm thickness using a cryostat (Leica CM1950, Buffalo Grove, IL). Antibodies specific to TH (rabbit polyclonal, 1:1000, Pel–Freez, Rogers, AR), human α–synuclein (mouse monoclonal, syn211, 1:500, Santa Cruz Biotech, Santa Cruz, CA) were used as suggested by manufacturers. Alexa 488 and Alexa 546–conjugated secondary antibodies (1:500, Life Technologies, Grand Island, NY) were used to visualize the staining. Fluorescence images were captured using a laser scanning confocal microscope (LSM 510; Zeiss, Thornwood, NJ). The images were presented as either a single optic layer after acquisition in z–series stack scans at 2–3 μm intervals from individual fields or displayed as maximum intensity projections to represent confocal stacks.
For the quantitative co–localization assessments, images from serial sections were taken and exported to ImageJ (NIH, Bethesda, MD) for imaging analyses. Each image was split into individual channels for SNCA (488 nm) and TH (546 nm). Cell bodies positive for TH were first selected using the polygon selection tool and then subjected to measurement by mean optical intensities. The mean intensities were then compared to the identical regions in SNCA channel. SNCA intensities below a set threshold were counted as being negative. The overall percentages of positive SNCA cells were then compared between the ages of 1 m and 16–18 m.
According to the mouse brain in stereotaxic coordinates (3rd edition, Keith B.J. Franklin and George Paxinos), a series of coronal sections across the midbrain (30 μm per section, every fourth section from Bregma −2.54 mm to −4.24 mm) were chosen and processed for TH staining as described above and visualized using a widefield microscope (Axio Imager A1; Zeiss). We examined 16 sections per brain at 40x magnification. The number of TH positive neurons was assessed using the Optical Fractionator Workflow in Stereo Investigator 11 (MicroBrightField Inc, Williston, VT). The sampling scheme was designed to have coefficient of error (CE) less than 10 % in order to get reliable results. A pilot counting of samples was performed to achieve a total marking of >200 cells, which generally yields CE <10 %. Once the pilot cells counting had completed, the CE was calculated. The counting parameters would be adjusted based on the CE value. To achieve CE <10 %, normally 12 series sections with total 100 counting frames and on average 2 cells per frame would be counted. The final parameters for these studies were: grid size 150x120μm and frame size 50x50μm. Three or more mice were used per genotype at each time point.
Tissue fractionation and Western blot
Striatum tissues were homogenized with 10 volumes of sucrose buffer (0.32 M sucrose, 1 mM NaHCO3, 1 mM MgCl2, and 0.5 mM CaCl2, plus protease and phosphatase inhibitor cocktails) and centrifuged at 10,000 g for 10 min. Protein concentrations in supernatant were measured by BCA (Thermo Fisher Scientific). Proteins were size–fractioned by 4–12 % NuPage BisTris– polyacrylamide gel electrophoresis (Life Technologies) using MES running buffer (Life Technologies). After transfer to nitrocellulose membranes, the membranes were immunoblotted with the appropriate dilutions of the primary antibody: human α–syn (syn211, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA) and α–tubulin (DM1A, 1:2000; Santa Cruz Biotechnology, Santa Cruz, CA. Signals were visualized with fluorescent secondary antibodies and quantified with ImageJ.
Statistical analysis was performed using Graphpad Prism 5 (Graphpad Software Inc. La Jolla, CA). Data were presented as mean ± SEM. Statistical significances were determined by comparing means of different groups and conditions using unpaired Student t–test or one–way ANOVA with post hoc Tukey test.
Transgenic hα–syn is unable to undergo long–range propagation
Since the transcription factor paired–like homeodomain 3 (Pitx3) is only expressed by subpopulations of midbrain DA neurons , previously we inserted tetracycline transactivator (tTA) coding sequence into the 3’–untranslated region of mouse Pitx3 gene to generate Pitx3–tTA knock–in mice, allowing tTA selectively expressed in midbrain DA neurons . In this so–called “tet–off” system, tTA can turn on the expression of any transgene under the control of tetracycline operator (tetO) . In the absence of such a transgene, this line of mice has no transgenic expression in the midbrain (Fig. 1a, b). Thus, to test whether hα–syn would induce the aggregation of endogenous mouse α–syn (mα–syn) in SNc DA neurons, we stained the midbrain sections of 18–month–old tetO–SNCA single transgenic and Pitx3–tTA heterozygous knock–in mice with an antibody that recognizes both mouse and human α–syn (m/hα–syn). We observed a similar number of small m/hα–syn–positive puncta in the SNc DA neurons of tetO–SNCA and control Pitx3–tTA mice (Fig. 1c), indicating a lack of recruitment of endogenous α–syn. Together, these observations suggest a lack of long–range transneuronal propagation of transgenic hα–syn into SNc DA neurons during aging.
α–synuclein is not transmitted from presynaptic terminals into SNc DA neurons
α–synuclein is unable to undergo cell–to–cell transmission between SNc DA neurons
We show here that transgenic hα–syn does not show detectable propagation to nigrostriatal DA neurons in various mouse models. We first used tetO–SNCA single transgenic mice to show that we could not observe long–range propagation of hα–syn into SNc DA neurons. These mice have no transgenic hα–syn expression in the nigrostriatal pathway; however, they do have “leaky”, non–specific hα–syn expression in other brain regions (i.e. hippocampus, cortex, and cerebellum). Any of these other regions could have played a role being a source of α–syn if the protein could indeed propagate. We performed immunohistochemical experiments on young and aged mice to see if we can observe hα–syn–positive staining anywhere in the SNc DA neurons of aged animals. However, these experiments gave no indication that long–range propagation was present in SNCA mice.
The following experiment tested propagation that may occur through neuronal projections from neighboring brain regions. For these experiments, we utilized a line of mice, Drd1a–rtTA::tetO–SNCA, which had hα–syn expression in the striatum and SNr, modeling the direct pathway of the basal ganglia. At 1–month of age, these mice exhibited no hα–syn expression in the SNc DA neurons. If propagation was present, we should be able to see hα–syn expression at later ages in these mice. This may have occurred as transmission directly to the SNc from the SPNs that form synapses onto SNc DA neurons . However, as with the previous experiments, we found no evidence of hα–syn being present in the SNc, again showing that there was no evident propagation.
Many studies have shown the ability of α–syn to propagate with the use of stereotaxic injections of preformed fibrils and have provided very convincing data for the ability of α–syn to behave as a prion, both in neurons and in glial cells . However, these studies often take advantage of artificial injections or inoculations, which may not be as applicable in a clinical, physiological setting. Therefore, alternative explanations to the prion hypothesis cannot be dismissed, including oxidative stress, excitotoxicity, neuroinflammation, and loss of neurotrophic factor support. These alternative explanations are not mutually exclusive and may potentially induce pathogenesis in a synergistic manner. Future studies should focus on microglial activation and other inflammatory responses in the brain resulting from intracerebral injections and inoculations. In addition, further scrutiny into the effect of inflammation on α–syn expression can provide answers about the causes and mechanisms by which α–syn adopts its abnormal prion–like qualities.
This work was supported by the intramural research program of National Institute on Aging (HC: AG-000928, 929). The authors would like to thank members of Cai lab for providing various supports.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Thomas B, Beal MF. Parkinson’s disease. Hum Mol Genet. 2007;16(Spec No. 2):R183–94. doi:https://doi.org/10.1093/hmg/ddm159.View ArticlePubMedGoogle Scholar
- Tolosa E, Pont-Sunyer C. Progress in defining the premotor phase of Parkinson’s disease. J Neurol Sci. 2011;310(1–2):4–8. doi:https://doi.org/10.1016/j.jns.2011.05.027.View ArticlePubMedGoogle Scholar
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40. doi:https://doi.org/10.1038/42166.View ArticlePubMedGoogle Scholar
- Picconi B, Piccoli G, Calabresi P. Synaptic dysfunction in Parkinson’s disease. Adv Exp Med Biol. 2012;970:553–72. doi:https://doi.org/10.1007/978-3-7091-0932-8_24.View ArticlePubMedGoogle Scholar
- Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A. Genetics of Parkinson’s disease and parkinsonism. Ann Neurol. 2006;60(4):389–98. doi:https://doi.org/10.1002/ana.21022.View ArticlePubMedGoogle Scholar
- Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.View ArticlePubMedGoogle Scholar
- Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72(1):57–71. doi:https://doi.org/10.1016/j.neuron.2011.08.033.PubMed CentralView ArticlePubMedGoogle Scholar
- Aulic S, Le TT, Moda F, Abounit S, Corvaglia S, Casalis L, et al. Defined alpha-synuclein prion-like molecular assemblies spreading in cell culture. BMC Neurosci. 2014;15:69. doi:https://doi.org/10.1186/1471-2202-15-69.PubMed CentralView ArticlePubMedGoogle Scholar
- Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949–53. doi:https://doi.org/10.1126/science.1227157.PubMed CentralView ArticlePubMedGoogle Scholar
- Luk KC, Kehm VM, Zhang B, O’Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209(5):975–86. doi:https://doi.org/10.1084/jem.20112457.PubMed CentralView ArticlePubMedGoogle Scholar
- Betemps D, Verchere J, Brot S, Morignat E, Bousset L, Gaillard D, et al. Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological alpha-synuclein by enhanced ELISA. Acta Neuropathol Commun. 2014;2:29. doi:https://doi.org/10.1186/2051-5960-2-29.PubMed CentralView ArticlePubMedGoogle Scholar
- Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, et al. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci U S A. 2013;110(48):19555–60. doi:https://doi.org/10.1073/pnas.1318268110.PubMed CentralView ArticlePubMedGoogle Scholar
- Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez-Villalba A, et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75(3):351–62. doi:https://doi.org/10.1002/ana.24066.View ArticlePubMedGoogle Scholar
- Luk KC, Lee VM. Modeling Lewy pathology propagation in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20 Suppl 1:S85–7. doi:https://doi.org/10.1016/S1353-8020(13)70022-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Jankowsky JL, Savonenko A, Schilling G, Wang J, Xu G, Borchelt DR. Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr Neurol Neurosci Rep. 2002;2(5):457–64.View ArticlePubMedGoogle Scholar
- Lin X, Parisiadou L, Sgobio C, Liu G, Yu J, Sun L, et al. Conditional expression of Parkinson’s disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J Neurosci. 2012;32(27):9248–64. doi:https://doi.org/10.1523/JNEUROSCI.1731-12.2012.PubMed CentralView ArticlePubMedGoogle Scholar
- Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A. 1992;89(12):5547–51.PubMed CentralView ArticlePubMedGoogle Scholar
- Smidt MP, Smits SM, Bouwmeester H, Hamers FP, van der Linden AJ, Hellemons AJ, et al. Early developmental failure of substantia nigra dopamine neurons in mice lacking the homeodomain gene Pitx3. Development. 2004;131(5):1145–55. doi:https://doi.org/10.1242/dev.01022.View ArticlePubMedGoogle Scholar
- Gerfen CR, Surmeier DJ. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci. 2011;34:441–66. doi:https://doi.org/10.1146/annurev-neuro-061010-113641.PubMed CentralView ArticlePubMedGoogle Scholar
- Gerfen CR. The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature. 1984;311(5985):461–4.View ArticlePubMedGoogle Scholar
- Watabe-Uchida M, Zhu L, Ogawa SK, Vamanrao A, Uchida N. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron. 2012;74(5):858–73. doi:https://doi.org/10.1016/j.neuron.2012.03.017.View ArticlePubMedGoogle Scholar
- Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell. 1985;41(3):1017–28.View ArticlePubMedGoogle Scholar
- Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8(8):2804–15.PubMedGoogle Scholar
- Bifsha P, Yang J, Fisher RA, Drouin J. Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra. PLoS Genet. 2014;10(12):e1004863. doi:https://doi.org/10.1371/journal.pgen.1004863.PubMed CentralView ArticlePubMedGoogle Scholar